Ampersand Biomedicines Funding: $165M Raised, Series B
Ampersand Biomedicines is a Biotech company based in Boston. It has raised $165M in total funding. Latest round: Series B.
Ampersand Biomedicines funding overview
Ampersand Biomedicines is a Biotech company based in Boston. Ampersand Biomedicines has raised $165M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series B announced in March 2025. The round record for Ampersand Biomedicines runs through 2025; nothing later has been disclosed. Investors on record include Flagship Pioneering, Eli Lilly. 2 distinct backers are named across the disclosed rounds.
Ampersand Biomedicines at a glance
Total raised
$165M
Latest round
Series B
Latest round date
March 2025
Industry
Biotech
Headquarters
Boston
Notable investors
Flagship Pioneering, Eli Lilly
Frequently asked about Ampersand Biomedicines funding
How much has Ampersand Biomedicines raised?
Ampersand Biomedicines has raised $165M in total disclosed funding across the rounds on record.
Who has invested in Ampersand Biomedicines?
Flagship Pioneering, Eli Lilly are named among the investors backing Ampersand Biomedicines.
What was the latest Ampersand Biomedicines funding round?
The most recent disclosed round is a Series B, announced in March 2025.
Where is Ampersand Biomedicines based?
Ampersand Biomedicines is based in Boston.
What sector does Ampersand Biomedicines operate in?
Ampersand Biomedicines is tracked under Biotech from Boston, with $165M in disclosed funding.
When did Ampersand Biomedicines last raise?
The last disclosed Ampersand Biomedicines round closed in March 2025 at Series B.
Ampersand Biomedicines totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related Biotech companies in Boston below to benchmark round size and investor mix.
